Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Receptos doses first patient in Phase 2 trial for RPC1063 in ulcerative colitis
Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.
Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.
Raxone®/Catena® (idebenone)
New Drugs Online report for idebenone
[Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation.]
Pericytes are required for blood-brain barrier integrity during embryogenesis.
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria.
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.
Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease.
Integrated genomic and prospective clinical studies show the importance of modular pleiotropy for disease susceptibility, diagnosis and treatment.
The potential teratogenic effects of interferon beta-1a (IFNβ-1a) and interferon beta-1b (IFNβ-1b) on in vitro embryonic development.
Thrombotic microangiopathy associated with use of interferon-beta.
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Tobacco Smoke-Induced Brain White Matter Myelin Dysfunction: Potential Co-Factor Role of Smoking in Neurodegeneration.
Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE).
Evaluation of pattern-reversal visual evoked potential in patients with neuromyelitis optica.
Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis.
3 Blockbuster Drugs Losing Patent Protection in 2013's Final Months
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
Zebrafish myelination: a transparent model for remyelination?
Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF-α Release from Activated Microglia and TNF-α Converting Enzyme Activity.

Pages